Protalix BioTherapeutics(NYSEMKT) PLX

Protalix BioTherapeutics makes medicines for people with rare diseases. The company uses plant cells to produce these specialized proteins. These treatments help patients manage life-altering genetic conditions.

What Protalix Makes

• Elfabrio: Enzyme replacement therapy for adults with Fabry disease; commercialized globally through licensing and supply agreements with Chiesi Farmaceutici S.p.A.
• Elelyso: Treatment for Gaucher disease in adults and children; marketed and sold globally by Pfizer except in Brazil.
• BioManguinhos Alfataliglicerase: Specialty Gaucher disease treatment; provided to the Brazilian Ministry of Health through a technology transfer agreement.
• Pipeline Candidates: Development-stage proteins including PRX-115 for uncontrolled gout and PRX-119 for neutrophil-related diseases.

Recent Wins and Expansion

• Received a $25.0 million milestone payment from Chiesi in 2026 following European regulatory approval for a new dosing schedule.
• Secured a patent term extension in May 2026 that protects Elfabrio in the U.S. until Nov. 17, 2035.
• Obtained orphan drug marketing authorization for Elfabrio in South Korea in May 2026 through a local distributor.
• Issued a new U.S. patent for the PRX-115 uricase product candidate in July 2026.

Why Plant Cells Matter

Protalix uses a proprietary ProCellEx system to manufacture complex proteins within plant cells instead of animal cells. This industrial-scale bioreactor technology produces recombinant proteins designed to treat rare diseases with significant unmet needs.

Profitability and Sales Growth

• Total revenue was $53.6 million for the six-month period ended June 30, 2026, up from $25.8 million in the prior year.
• Net income reached $22.1 million during the six months ended June 30, 2026, up from a net loss of $3.5 million in 2025.
• Revenues from selling goods rose 28% year over year for the three-month period ended June 30, 2026.
• Cash and short-term bank deposits totaled $40.7 million as of June 30, 2026.

The Big Picture

Protalix has evolved into a commercial-stage biotechnology firm using a unique plant-based protein production platform. The company maintains its growth through global licensing agreements and a deepening pipeline of rare disease treatments.